Navigation Links
Mayo Clinic Study Identifies Potential Causes of Young-Onset Dementia
Date:4/15/2008

ROCHESTER, Minn., April 15, 2008 /PRNewswire-USNewswire/ -- A new Mayo Clinic study found that young-onset dementia often is caused by neurodegenerative or autoimmune/inflammatory conditions, but only rarely by Alzheimer's disease. This differs substantially from the common causes of dementia in older individuals (Alzheimer's disease and other neurodegenerative dementias). These findings will be presented at the American Academy of Neurology Annual Meeting in Chicago on April 15.

Dementia represents a progressive decline in a person's cognitive function that affects the ability to think, speak, reason, remember and move. The most common forms of dementia are Alzheimer's disease, vascular dementia and Lewy body dementia. Approximately 12 in 100,000 people may develop dementia prior to age 45, called young-onset dementia.

"After seeing several patients in their 20s who had graduated from college and were suddenly experiencing severe dementia, I wanted to try to provide answers as to what was causing dementia at such young ages," says Brendan Kelley, M.D., an author of this study and a neurologist at Mayo Clinic.

Dr. Kelley and a team of Mayo Clinic physicians set out to identify the characteristics and causes of dementia prior to age 45. They identified 235 individuals, ages 17 to 45, who previously had normal cognitive function and were evaluated for progressive cognitive decline at Mayo Clinic from 1996 to 2006. In one-third of patients, the dementia was caused by a neurodegenerative disorder such as frontotemporal dementia, Huntington's disease or familial prion disease. However, Alzheimer's disease was an uncommon cause. In 20 percent of patients, young-onset dementia was caused by autoimmune or inflammatory conditions such as multiple sclerosis, autoimmune encephalopathy or neuropsychiatric lupus. According to Dr. Kelley, this is an important finding, because many of these diseases may have specific treatments.

Additionally, 10 percent had metabolic disorders commonly thought to occur mainly in children. In 19 percent of the patients, the cause of young-onset dementia remained unknown despite thorough and exhaustive evaluation.

"This study sheds light on the fact that young people do, in fact, develop dementia, and that there are important differences between the causes of young-onset dementia and the causes of dementia in older individuals," says Dr. Kelley. "However, more research is required to better understand the characteristics and most effective treatments for young patients with dementia."

Brad Bishop is one of the patients who influenced Dr. Kelley to pursue this research. Bishop, age 27, was diagnosed with frontotemporal dementia in 2006. According to his parents, he was an energetic, thoughtful, caring and intelligent young man who graduated from college in 2004 with a double major in business and computers. His symptoms of dementia started around age 21, including withdrawal from people outside his family, inappropriate behavior, poor financial judgment and progressive decline in cognitive function. Now, Bishop needs around-the-clock care as his brain continues to deteriorate.

"We are seeing our son disappear before our eyes, little bit by little bit," says Susan Bishop, his mother. "We'll always hope for a miracle, but realistically we just want Brad to be safe, happy, comfortable and treated with the dignity and respect that he deserves...every day we have with him is a gift."

Dr. Kelley and his team will continue to learn more by prospectively following patients like Bishop to better understand what causes early-onset dementia. Other members of the Mayo Clinic research team included Bradley Boeve, M.D., and Keith Josephs, M.D.

To obtain the latest news releases from Mayo Clinic, go to http://www.mayoclinic.org/news. MayoClinic.com (http://www.mayoclinic.com) is available as a resource for your health stories.


'/>"/>
SOURCE Mayo Clinic
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
4. Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinsons Disease
5. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
6. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
7. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
8. Presentation of HeartWare Clinical Results
9. Clinically Proven Treatment Offers Help to Rosacea Sufferers
10. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
11. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... poised to grow in 2017-2023. Various reasons for growth ... obese population, higher incidences of chronic diseases, high recovery ... mobility aid services. Medical lifting sling refers to ... with limited mobility. These slings connect to the lift ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
Breaking Medicine Technology:
(Date:12/9/2016)... Woodland Hills, CA (PRWEB) , ... December 09, ... ... center for young adults, celebrated its 10th anniversary with the grand opening of ... Hills, California. The successful event spanned two days, December 2-3, and was attended ...
(Date:12/9/2016)... NJ (PRWEB) , ... December 09, 2016 , ... ... Founders Ball at The Pierre Hotel in New York, NY, on December 3rd, ... benefactors, dignitaries and physicians attended the annual event, which raised over $1 million ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic ... (PCN) during the summer of 2016. The program was made possible by a ... States Department of Health and Human Services Administration. The broadcast, Use Your ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...
Breaking Medicine News(10 mins):